Born to survive: how cancer cells resist CAR T cell therapy

Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemoine, Jean, Ruella, Marco, Houot, Roch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609883/
https://www.ncbi.nlm.nih.gov/pubmed/34809678
http://dx.doi.org/10.1186/s13045-021-01209-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609883/
https://www.ncbi.nlm.nih.gov/pubmed/34809678
http://dx.doi.org/10.1186/s13045-021-01209-9

Ejemplares similares